Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2025)

Serina Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at -$5.2 million for Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities fell 137.95% year-over-year to -$5.2 million; the TTM value through Jun 2025 reached -$5.2 million, down 137.95%, while the annual FY2024 figure was $2.5 million, 48.52% down from the prior year.
  • Total Non-Current Liabilities for Q2 2025 was -$5.2 million at Serina Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $20.4 million in Q4 2022 and bottomed at -$8.9 million in Q1 2024.
  • The 4-year median for Total Non-Current Liabilities is $4.9 million (2023), against an average of $5.5 million.
  • The largest YoY upside for Total Non-Current Liabilities was 128.93% in 2025 against a maximum downside of 137.95% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $20.4 million in 2022, then tumbled by 76.16% to $4.9 million in 2023, then tumbled by 48.52% to $2.5 million in 2024, then tumbled by 307.72% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Total Non-Current Liabilities are -$5.2 million (Q2 2025), $2.6 million (Q1 2025), and $2.5 million (Q4 2024).